1 / 14

Targeting the Renin Angiotensin System: Past, Present and Future

Cardio Diabetes Master Class October 15-17, 2010, Dublin. Targeting the Renin Angiotensin System: Past, Present and Future. Slide lecture prepared and held by:. Thomas Unger, MD Charité University Medicine Berlin Germany. Renin. Angiotensin I. Ang-(1-9). ACE2. NEP. ACE. Ang-(1-7).

tynice
Download Presentation

Targeting the Renin Angiotensin System: Past, Present and Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cardio Diabetes MasterClass October 15-17, 2010, Dublin Targeting the Renin Angiotensin System:Past, Present and Future Slide lecture prepared and held by: Thomas Unger, MD Charité University Medicine Berlin Germany

  2. Renin Angiotensin I Ang-(1-9) ACE2 NEP ACE Ang-(1-7) Angiotensin II Mas-R ACE Ang-(1-5) ANG II ANG II AT1 AT2 The Renin-Angiotensin-System Angiotensinogen

  3. Angiotensin effects on the nephron + + + + + - Angiotensin II Pglom Aldosterone Proximal Na+- reabsorption  Na+-reabsorption 

  4. Angiotensin II via AT1 RAS in cardiovascular pathology Risk factors: diabetes, obesity, smoking, age Vasoconstriction Vascular hypertrophy Endothelial dysfunction Atherosclerosis Apoptosis LVH Fibrosis Arrhythmia Heart failure MI Death Stroke Cognitive dysfunction Vascular disease Hypertension Decreased GFR Proteinuria/albuminuria Glomerulosclerosis Pro-thrombotic state Renal failure Adapted from: Chung O. & Unger T., Am J Hypertens 1999;12:150S–156S

  5. ACE inhibitors ACE inhibitors CCR Drugs inhibiting the renin-angiotensin-aldosterone system Angiotensinogen Renin inhibitors Renin Bradykinin ANG I ACE ACE Aldosterone Aldosterone antagonists + Frag ANG II ments ANG II AT1 Receptor Blockers ANG II AT2 AT1

  6. LIFE study: Greater regression of LVH with ARB (losartan) than with β-blocker (atenolol) Change from baseline (%) in LVH determined by electrocardiography Proportion of patients with first event (%) 0 16 -2 Composite of CV Death, stroke and MI 14 -4 12 4.4% -6 10 Atenolol (n=4588) -8 8 9.0% -10 10.2% 6 Losartan (n=4605) -12 p < 0.0001 4 -14 Atenolol (n=4588) Losartan (n=4605) Adjusted Risk Reduction: 13.0%, p = 0.021 2 -16 15.3% 0 -18 p < 0.0001 0 6 12 18 24 30 36 42 48 54 60 66 CornellVoltage-Duration Product Sokolow-LyonVoltage Time (months) Discontinuation as a result of all adverse events, drug-related adverse events, and serious and serious and drug-related adverse events were significantly less common in losartan patients than atenolol patients. Dahlöf B et al. Lancet 2002

  7. ANG II: Progression of Chronic Renal Disease AT1 RA Renal disease ANG II ANG II ANG II ANG II Direct Cytotoxicity Vasoconstriction Inflammation Growth Effect Angiotensinogen NF- kB TNF-a Oxidative Stress Fibroblasts Tubule Cells Profibrotic Cytokines Chemoattractants Adhesion proteins Proliferation Differentation Matrix Inflammation Fibrosis Klahr et al., 2000

  8. Comparison of IDNT- and RENAAL-Results Relative Change vs Amlodipine-based or Control Therapy (%) Primary Endpoint IDNT RENAAL 0 - 5 - 10 - 15 - 16 % - 20 - 20 % - 25 - 23 % Irbesartan Losartan - 30 vs Control vs Control vs Amlodipine NNT = 15 Lewis E.J. et al., N. Engl. J. Med. 2001; 345: 851-60 ;Brenner B.M. et al., N. Engl. J. Med. 2001; 345: 861-9

  9. AT1R-Antagonism (Telmisartan) and PPAR RA p300 L ARB ARB PPARs RXR Anti-hypertensive Anti-inflammatory Anti-atherosclerotic Anti-diabetic PPRE Gene 5’ 3’ Schupp et al Circulation 2004 Benson et al Hypertension 2004 Clasen et al Hypertension 2005 Zhao Yi et al J Neurochem 2005 Schupp et al Diabetes 2005 Schupp et al Hypertension 2006 Angiotensin II AT1 AT2 Cell membrane Nuclear membrane

  10. ANG II ANG II AT1 AT2 Angiotensin-Receptors • Vasoconstriction • Na+-Retention • Aldosterone-Release • Vasodilation (?) • (Neuro-)regeneration • Proliferation • Fibrosis • Inflammation • Anti-Proliferation • Anti-Fibrosis • Anti-Inflammation

  11. Endothelial Cells AT2 transfection in vivo control Ang II control neointima injury injury + AT2 transfection Ang II+losartan Ang II+PD123177 Nakajima M et al. Proc Natl Acad Sci 1995 Stoll M et al. J Clin Invest 1995

  12. Compound21 C 21 ANG II Angiotensin AT2 Receptor The Key: Pharmacological Stimulation of a natural protective system ANG II AT2 • • NO Production • Vasodilation (?) Physiology/Pathophysiology: Endogenous tissue-protective system • • Anti-Proliferation • • Anti-Fibrosis • • Anti-Inflammation • (Neuro-)regeneration • Differentiation

  13. Compound 21: a biased agonist ? compound 21 R*1 Cardiomyocyte diameter anti-hypertrophic and anti-inflammatory responses 120 IL6-RLA (%) 100 80 60 40 20 0 TNFa TNFa + C21 TNFa + HC control R AT2R SHP-1 ATBP

  14. (pro)renin angiotensin II- dependent effects angiotensin I RERBs 4-5 fold (renin) angiotensinogen PLZF angiotensin II- independent effects (-) RER (+) cell number (+) proliferation (-) apoptosis RER-promoter PI3K-85α-promoter end-organ damage ? The Two Sides of Renin Receptor Stimulation RER cell membrane nuclear membrane - Schefe et al Circ Res 2006 Schefe et al J Hypertension 2008

More Related